Here's How the New Weight Loss Drugs Could Change Everything
There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Odd Lots →
The State of Weight-Loss Drugs
Money Talks: Why weight-loss drugs will reshape the world
What the Expanding Reach of Weight-Loss Drugs Means For Health Care 10/11/23
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.